CIK 0001655759 · Accelerated filer
ARVINAS, INC.
Sign in to watch- Ticker
- ARVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 472566120
- Phone
- 203-535-1456
- Business address
- 395 WINCHESTER AVE, 5 SCIENCE PARK, NEW HAVEN, CT, 06511
- Former names
- ARVINAS INC., ARVINAS HOLDING COMPANY, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,475
- in 1 filing, $1K under 10b5-1 plans
Net −$1,475. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-25 | Kennedy Edward Moore Jr. Director | Grant or award · Stock Option (right to buy) | +23,105 | 23,105 | ||
| 2025-06-25 | Cunningham Everett Director | Grant or award | +16,025 | 26,045 | ||
| 2025-06-25 | Cunningham Everett Director | Grant or award · Stock Option (right to buy) | +23,105 | 23,105 | ||
| 2025-06-25 | Norwalk Leslie V Director | Grant or award | +16,025 | 26,045 | ||
| 2025-06-25 | Norwalk Leslie V Director | Grant or award · Stock Option (right to buy) | +23,105 | 23,105 | ||
| 2025-06-24 | Saik Andrew Chief Financial Officer | Sale | −5,700 | $7.61 | $43K | 164,401 |
| 2025-06-17 | Cacace Angela M Chief Scientific Officer | Sale | −2,583 | $7.49 | $19K | 154,248 |
| 2025-05-09 | Loomis David K Chief Accounting Officer | Grant or award | +11,825 | 30,688 | ||
| 2025-05-09 | Loomis David K Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +18,100 | 18,100 | ||
| 2025-05-09 | Saik Andrew Chief Financial Officer | Grant or award | +59,600 | 170,101 | ||
| 2025-05-09 | Saik Andrew Chief Financial Officer | Grant or award · Stock Option (right to buy) | +91,000 | 91,000 | ||
| 2025-05-09 | Cacace Angela M Chief Scientific Officer | Grant or award | +59,600 | 156,831 | ||
| 2025-05-09 | Cacace Angela M Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +91,000 | 91,000 | ||
| 2025-05-09 | Berkowitz Noah Chief Medical Officer | Grant or award | +59,600 | 169,623 | ||
| 2025-05-09 | Berkowitz Noah Chief Medical Officer | Grant or award · Stock Option (right to buy) | +91,000 | 91,000 | ||
| 2025-03-18 | Berkowitz Noah Chief Medical Officer | Sale | −8,658 | $8.59 | $74K | 110,023 |
| 2025-02-24 | Loomis David K Chief Accounting Officer | Sale | −1,214 | $16.75 | $20K | 18,863 |
| 2025-02-24 | Cacace Angela M Chief Scientific Officer | Sale | −3,061 | $16.75 | $51K | 98,377 |
| 2025-02-24 | Cacace Angela M Chief Scientific Officer | Sale | −1,146 | $16.55 | $19K | 97,231 |
| 2025-02-24 | Taylor Ian President, R&D | Sale | −7,356 | $16.75 | $123K | 160,785 |
Page 4 of 10 · 184 trades